Table 2 Administration of modified mesenchymal stromal cells (MSCs) or/and native MSCs in combination with other modalities in liver failure preclinical models, especially acute liver failure (ALF)
Sources | Model | Intervention | Result (ref) |
|---|---|---|---|
Adipose tissue | Rat | MSCs plus Eugenol | Enhancing antifibrotic competencies of MSCs by eugenol through down-regulation of TGF-β/Smad axis [205] |
Bone marrow | Rat | MSC plus Neutrophil depletion | Amelioration of ALF in rats [206] |
Umbilical cord | Rat | MSC plus Icaritin | Enhancing the antiapoptotic capability of MSCs by promoting the HGF/c-Met pathway [131] |
Umbilical cord | Mice | HNF4α-overexpressing MSCs plus Hepatocyte | Improving the EGF release by HNF4α-UMSCs [207] |
Umbilical cord blood | Rat | VEGF165 -overexpressing MSCs | Induction of marked therapeutic influences on ALF [143] |
Bone marrow | Mice | CXCR4-overexpressing MSCs | Improved migration and reduced damaged tissue by stimulating hepatoprotective impacts [142] |
Amniotic fluid | Rat | IL-1-overexpressing MSCs | Improved liver function along with prolonged survival [145] |
NA | Swine | MSCs plus IL-lRa-loaded chitosan nanoparticles | Eliciting a synergistic impact by abrogating liver inflammation [136] |
Bone marrow | Rat | Dexmedetomidine and Midazolam primed MSCs | Enhancing the therapeutic merits of MSCs [208] |
Umbilical cord | Rat | MSCs plus G-CSF | Attenuation of liver damage by suppressing the generation of pro-inflammatory cytokines, alleviation of oxidative stress, and reducing liver cell loss [132] |
Bone marrow | Swine | MSCs plus IL-1R antagonism | Exerting synergistic influences by prohibiting the inflammation and apoptotic signaling [135] |
Bone marrow | Mice | MSCs seeded on human amniotic membranes (HAM) | Improving survival rate [209] |
Bone marrow | Mice | Poly lactic-co-glycolic acid (PLGA) scaffold loaded with MSCs | Stimulation of hepatoprotective impacts by paracrine factors [127, 128] |
Bone marrow | Mice | Regenerated silk fibroin (RSF) scaffold loaded with MSCs | Potentiating liver function by provoking angiogenesis [130] |